Read by QxMD icon Read

proteín creatinine ratio in urine in diabetic nephropathy

Riccardo Pofi, Daniela Fiore, Rita De Gaetano, Giuseppe Panio, Daniele Gianfrilli, Carlotta Pozza, Federica Barbagallo, Yang Kevin Xiang, Konstantinos Giannakakis, Susanna Morano, Andrea Lenzi, Fabio Naro, Andrea M Isidori, Mary Anna Venneri
Diabetic Nephropathy (DN) is the leading cause of end-stage renal disease. Preclinical and experimental studies show that PDE5 inhibitors (PDE5is) exert protective effects in DN improving perivascular inflammation. Using a mouse model of diabetic kidney injury we investigated the protective proprieties of PDE5is on renal hemodynamics and the molecular mechanisms involved. PDE5i treatment prevented the development of DN-related hypertension (P < 0.001), the increase of urine albumin creatinine ratio (P < 0...
March 15, 2017: Scientific Reports
Salem Almaani, Lee A Hebert, Brad H Rovin, Daniel J Birmingham
Patients enrolled in the African American Study of Kidney Disease and Hypertension (AASK) Cohort Study who exhibited overt proteinuria have been reported to show high nonalbumin proteinuria (NAP), which is characteristic of a tubulopathy. To determine whether African American Study of Kidney Disease and Hypertension nephropathy (AASK-N) is a tubulopathy, we obtained urine samples of 37 patients with AASK-N, with 24-hour protein-to-creatinine ratios (milligrams per milligram) ranging from 0.2 to 1.0, from the National Institute of Diabetes and Digestive Kidney Diseases repository and tested for seven markers of tubular proteinuria...
January 19, 2017: Journal of the American Society of Nephrology: JASN
Koji Kitagori, Hajime Yoshifuji, Takuma Oku, Chiyomi Sasaki, Hitomi Miyata, Keita P Mori, Toshiki Nakajima, Koichiro Ohmura, Daisuke Kawabata, Naoichiro Yukawa, Yoshitaka Imura, Kosaku Murakami, Ran Nakashima, Takashi Usui, Takao Fujii, Kaoru Sakai, Motoko Yanagita, Yoshitaka Hirayama, Tsuneyo Mimori
We assessed the utility of two forms of osteopontin (OPN), OPN full and its cleaved form (OPN N-half), in plasma and urine as markers of disease activity in lupus nephritis (LN). Samples were collected from patients with systemic lupus erythematosus (SLE) (LN: N = 29, non-LN: N = 27), IgA nephropathy (IgAN) (N = 14), minimal change nephrotic syndrome (MCNS) (N = 5), diabetic nephropathy (DN) (N = 14) and healthy volunteers (HC) (N = 17). While there was no significant difference in urine OPN full concentration between groups, urine OPN N-half concentration was significantly higher in patients with LN than HC (p < 0...
2016: PloS One
Jong Ho Kim, Sang Soo Kim, In Joo Kim, Min Jin Lee, Yun Kyung Jeon, Bo Hyun Kim, Sang Heon Song, Yong Ki Kim
AIMS: Multiple biomarkers have emerged as a reliable predictor of the progression of diabetic nephropathy. The aim of this study was to pursue a more simple and practical predictor that can be applied in clinical practice. METHODS: The urine albumin-to-creatinine ratio (ACR), the nonalbumin protein-to-creatinine ratio (NAPCR), and the levels of six biomarkers were measured in 73 patients with type 2 diabetes and estimated glomerular filtration rates (eGFRs)≥60mL/min/1...
November 12, 2016: Journal of Diabetes and its Complications
M Jija Jose, Vipin Varkey, R Chandni, P A Zubaida, Jean Maliekkal
OBJECTIVE: To study the relation of smoking and abnormal renal function in type 2 diabetes mellitus by estimating urine protein- creatinine ratio, blood urea, serum creatinine, glomerular filtration rate and serum lipid profile in selected subjects. METHODS: Diabetic patients who attended the Diabetic Clinic, Medical College, Kozhikode were enrolled in the study. The study duration was 6 months, from July 2008 to December 2008. It was conducted in four groups of 40 subjects: diabetic smokers, diabetic non-smokers, non-diabetic smokers and non-diabetic non-smokers...
July 2016: Journal of the Association of Physicians of India
Yunqiang He, Ziqiang Xu, Mingshi Zhou, Minmin Wu, Xuehai Chen, Silu Wang, Kaiyan Qiu, Yong Cai, Hongxing Fu, Bicheng Chen, Mengtao Zhou
Objective. Diabetic nephropathy (DN) is a common microvascular complication of diabetes mellitus, and insulin therapy has many side effects in the treatment of DN. Islet transplantation has emerged as a promising therapy for diabetic patients. This study was established to investigate its advantageous effects in a rat model of early DN. Methods. Streptozotocin was administered to the rats to induce diabetes. Twelve weeks later, the diabetic rats were divided into 3 groups: the islet-transplanted group (IT group), the insulin-treated group (IN group), and the untreated group (DN group)...
2016: Journal of Diabetes Research
Yuichiro Ueda, Hiroki Ishii, Taisuke Kitano, Mitsutoshi Shindo, Haruhisa Miyazawa, Kiyonori Ito, Keiji Hirai, Yoshio Kaku, Honami Mori, Taro Hoshino, Susumu Ookawara, Masafumi Kakei, Kaoru Tabei, Yoshiyuki Morishita
BACKGROUND: We investigated the effects and safety of linagliptin as an add-on therapy in patients with advanced-stage diabetic nephropathy (DMN) taking renin-angiotensin-aldosterone system (RAAS) blockers. METHOD: Twenty advanced-stage DMN patients (estimated glomerular filtration rate (eGFR): 24.5 ± 13.4 mL/min/1.73 m(2)) taking RAAS blockers were administered 5 mg/day linagliptin for 52 weeks. Changes in glucose and lipid metabolism and renal function were evaluated...
2016: Drug Target Insights
James Voelker, Paul H Berg, Matthew Sheetz, Kevin Duffin, Tong Shen, Brian Moser, Tom Greene, Samuel S Blumenthal, Ivan Rychlik, Yoram Yagil, Philippe Zaoui, Julia B Lewis
TGF-β has been implicated as a major pathogenic factor in diabetic nephropathy. This randomized, double-blind, phase 2 study assessed whether modulating TGF-β1 activity with a TGF-β1-specific, humanized, neutralizing monoclonal antibody (TGF-β1 mAb) is safe and more effective than placebo in slowing renal function loss in patients with diabetic nephropathy on chronic stable renin-angiotensin system inhibitor treatment. We randomized 416 patients aged ≥25 years with type 1 or type 2 diabetes, a serum creatinine (SCr) level of 1...
March 2017: Journal of the American Society of Nephrology: JASN
Parisa Golriz Khatami, Alireza Soleimani, Nasrin Sharifi, Esmat Aghadavod, Zatollah Asemi
BACKGROUND: Limited data are available that evaluated the effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with diabetic nephropathy (DN). OBJECTIVE: This study was conducted to evaluate the effects of high-dose vitamin E supplementation on biomarkers of kidney injury, inflammation, and oxidative stress in patients with DN. METHODS: This randomized double-blind placebo-controlled clinical trial was carried out among 60 patients with DN...
July 2016: Journal of Clinical Lipidology
Wenchao Hu, Li Chen
Objective. Adropin is a newly identified regulatory protein encoded by the Enho gene and is critically involved in energy homeostasis and insulin sensitivity. This study aims to determine the correlation of serum adropin concentrations with diabetic nephropathy (DN). Methods. This study consisted of 245 patients with type 2 diabetes mellitus (T2DM) and 81 healthy subjects. Then T2DM patients were divided into normoalbuminuria, microalbuminuria, and macroalbuminuria subgroups based on urine albumin to creatinine ratio (ACR)...
2016: Mediators of Inflammation
Kam Wa Chan, Tai Pang Ip, Alfred Siu Kei Kwong, Sing Leung Lui, Gary Chi Wang Chan, Benjamin John Cowling, Wai Han Yiu, Dickson Wai Leong Wong, Yang Liu, Yibin Feng, Kathryn Choon Beng Tan, Loretta Yuk Yee Chan, Joseph Chi Kam Leung, Kar Neng Lai, Sydney Chi Wai Tang
INTRODUCTION: Diabetes mellitus and diabetic nephropathy (DN) are prevalent and costly to manage. DN is the leading cause of end-stage kidney disease. Conventional therapy blocking the renin-angiotensin system has only achieved limited effect in preserving renal function. Recent observational data show that the use of Chinese medicine (CM), a major form of traditional medicine used extensively in Asia, could reduce the risk of end-stage kidney disease. However, existing clinical practice guidelines are weakly evidence-based and the effect of CM remains unclear...
August 5, 2016: BMJ Open
Sawako Kato, Masahiko Ando, Toshihiro Mizukoshi, Takanobu Nagata, Takayuki Katsuno, Tomoki Kosugi, Naotake Tsuboi, Shoichi Maruyama
Proteinuria is an established risk factor for diabetic nephropathy. Recent studies indicate that some xanthine oxidase inhibitors have a renoprotective effect. The aim of this study was to assess whether topiroxostat reduces albuminuria in hyperuricemic patients with diabetic nephropathy and overt proteinuria. The ETUDE study is an ongoing 24-week, multicenter, open-label, randomized (1:1), parallel group study involving hyperuricemic patients with diabetic nephropathy (estimated glomerular filtration rate [eGFR] ≥ 20 mL/min/1...
May 2016: Nagoya Journal of Medical Science
Afzal Ahmad, Poornima Manjrekar, Charu Yadav, Ashish Agarwal, Rukmini Mysore Srikantiah, Anupama Hegde
AIM: This study aimed at evaluation of ischemia-modified albumin (IMA), malondialdehyde (MDA), and advanced oxidative protein products (AOPP) as markers of vascular injury in diabetic nephropathy (DN) with derivation of cutoff values for the same. MATERIALS AND METHODS: Study population comprised 60 diabetes patients and 30 controls, with diabetes patients further categorized into three groups based on urine albumin/creatinine ratio (UACR) of <30 mg/g (diabetes without microalbuminuria), 30-300 mg/g (early DN), and >300 mg/g of creatinine (overt DN)...
2016: Biomarker Insights
Boris B Betz, Sara J Jenks, Andrew D Cronshaw, Douglas J Lamont, Carolynn Cairns, Jonathan R Manning, Jane Goddard, David J Webb, John J Mullins, Jeremy Hughes, Stela McLachlan, Mark W J Strachan, Jackie F Price, Bryan R Conway
Many diabetic patients suffer from declining renal function without developing albuminuria. To identify alternative biomarkers for diabetic nephropathy (DN) we performed urinary peptidomic analysis in a rodent model in which hyperglycemia and hypertension synergize to promote renal pathologic changes consistent with human DN. We identified 297 increased and 15 decreased peptides in the urine of rats with DN compared with controls, including peptides derived from proteins associated with DN and novel candidate biomarkers...
May 2016: Kidney International
Xin Qian, Xinghui Li, Fenfen Ma, Shanshan Luo, Ruowen Ge, Yizhun Zhu
In this work, we demonstrated for the first time that S-propargyl-cysteine (SPRC, also named as ZYZ-802), a novel hydrogen sulfide (H2S)-releasing compound, had renoprotective effects on streptozotocin (STZ)-induced diabetic kidney injury. SPRC treatment significantly reduced the level of creatinine, kidney to body weight ratio and in particular, markedly decreased 24-h urine microalbuminuria excretion. SPRC suppressed the mRNA expression of fibronectin and type IV collagen. In vitro, SPRC inhibited mesangial cells over-proliferation and hypertrophy induced by high glucose...
May 13, 2016: Biochemical and Biophysical Research Communications
Anuja P Shah, Jenny I Shen, Ying Wang, Lili Tong, Youngju Pak, Ali Andalibi, Janine A LaPage, Sharon G Adler
BACKGROUND: We tested minocycline as an anti-proteinuric adjunct to renin-angiotensin-aldosterone system inhibitors (RAASi) in diabetic nephropathy (DN) and measured urinary biomarkers to evaluate minocycline's biological effects. METHODS: HASH(0x5166c18) DESIGN: Prospective, single center, randomized, placebo-controlled, intention-to-treat pilot trial. Inclusion. Type 2 diabetes/DN; Baseline creatinine clearance >30 mL/min; proteinuria ≥1...
2016: PloS One
Hanan S Anbar, George S G Shehatou, Ghada M Suddek, Nariman M Gameil
This work was designed to investigate the effects of levocetirizine, a histamine H1 receptor antagonist, on diabetes-induced nephropathy and vascular disorder, in comparison to an angiotensin II receptor antagonist, losartan. Diabetes was induced in male Sprague Dawley rats by a single intraperitoneal injection of streptozotocin (50mg/kg). Diabetic rats were divided into three groups; diabetic, diabetic-levocetirizine (0.5mg/kg/day) and diabetic-losartan (25mg/kg/day). Treatments were started two weeks following diabetes induction and continued for additional eight weeks...
June 5, 2016: European Journal of Pharmacology
Bo Hwan Kim, Eun Soo Lee, Ran Choi, Jarinyaporn Nawaboot, Mi Young Lee, Eun Young Lee, Hyeon Soo Kim, Choon Hee Chung
PURPOSE: Diabetic nephropathy is a serious complication of type 2 diabetes mellitus, and delaying the development of diabetic nephropathy in patients with diabetes mellitus is very important. In this study, we investigated inflammation, oxidative stress, and lipid metabolism to assess whether curcumin ameliorates diabetic nephropathy. MATERIALS AND METHODS: Animals were divided into three groups: Long-Evans-Tokushima-Otsuka rats for normal controls, Otsuka-Long-Evans-Tokushima Fatty (OLETF) rats for the diabetic group, and curcumin-treated (100 mg/kg/day) OLETF rats...
May 2016: Yonsei Medical Journal
Nagham M S El-Beblawy, Nevine G Andrawes, Eman Abdel Rahman Ismail, Basem El-Said Enany, Heba S Abou El-Seoud, Marwa A Erfan
Orosomucoid is an acute-phase serum protein that is upregulated in urine samples of patients with diabetic nephropathy. We assessed serum and urinary orosomucoid levels in children and adolescents with type 1 diabetes and their relation to microvascular complications and carotid intima-media thickness (CIMT). Sixty patients with type 1 diabetes were divided into 2 groups according to the presence of microvascular complications and compared with 60 healthy controls. High-sensitivity C-reactive protein (hs-CRP), hemoglobin A1c (HbA1c), urinary albumin-creatinine ratio (UACR), serum and urinary orosomucoid, and CIMT were assessed...
November 2016: Clinical and Applied Thrombosis/hemostasis
Vincent P O'Reilly, Limy Wong, Claire Kennedy, Louise A Elliot, Shane O'Meachair, Alice Marie Coughlan, Eoin C O'Brien, Michelle M Ryan, Diego Sandoval, Emma Connolly, Gerjan J Dekkema, Jiaying Lau, Wayel H Abdulahad, Jan-Stephan F Sanders, Peter Heeringa, Colm Buckley, Cathal O'Brien, Stephen Finn, Clemens D Cohen, Maja T Lindemeyer, Fionnuala B Hickey, Paul V O'Hara, Conleth Feighery, Sarah M Moran, George Mellotte, Michael R Clarkson, Anthony J Dorman, Patrick T Murray, Mark A Little
A specific biomarker that can separate active renal vasculitis from other causes of renal dysfunction is lacking, with a kidney biopsy often being required. Soluble CD163 (sCD163), shed by monocytes and macrophages, has been reported as a potential biomarker in diseases associated with excessive macrophage activation. Thus, we hypothesized that urinary sCD163 shed by crescent macrophages correlates with active glomerular inflammation. We detected sCD163 in rat urine early in the disease course of experimental vasculitis...
September 2016: Journal of the American Society of Nephrology: JASN
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"